Risk Management in Blood Transfusion: The Virtue of Reality: Proceedings of the Twenty-Third International Symposium on Blood Transfusion, Groningen 1998, organized by the Blood Bank Noord Nederland / Edition 1by Cees Smit Sibinga
Pub. Date: 10/31/1999
Publisher: Springer US
Risk Management in Blood Transfusion is unique in providing a fairly c omplete overview of the various aspects of risk perception in relation to blood transfusion. Inspired by an unequalled authority as Dr. Harv ey Alter, an extremely competent and talented panel of authors provide s a balanced opinion on how to manage risk in blood transfusion; a tru e virtue of
Risk Management in Blood Transfusion is unique in providing a fairly c omplete overview of the various aspects of risk perception in relation to blood transfusion. Inspired by an unequalled authority as Dr. Harv ey Alter, an extremely competent and talented panel of authors provide s a balanced opinion on how to manage risk in blood transfusion; a tru e virtue of reality.
- Springer US
- Publication date:
- Developments in Hematology and Immunology (closed) Series, #34
- Edition description:
- Product dimensions:
- 9.21(w) x 6.14(h) x 0.63(d)
Table of ContentsModerators and Speakers. Foreword. I: Perception of Risk. Does Perceived Risk Withhold People from Donating Blood?; Ch.A.J. Vlek. Managing Risks from an Insurer's Perspective; A. Oosterlee. Bad Blood or the Elixir of Life? Perceived Risk of Blood Transufions; M.L. Finucane. The Role of Cost-Effectiveness Analysis in Defining Transfusion Medicine Policy; J.P. AuBuchon. Discussion. II: Management of Infection Defined Risks. Risks of Transfusion-Transmitted Infection: A Comparative Analysis of Then and Now; H.J. Alter. Prevention of Transfusion Transmissible Infections: The Impact of the Recent Past on Current Decision Making; S.H. Kleinman. Management of Infection-Defined Risks; R.Y. Dodd. Closing the Window of Early HIV Infection by Incorporation of HIV p24 Ag Detection; J. van Binsbergen. GAT Testing: Added Value? L. Noël. Discussion. III: Management of Immune Defined Risks. The Role of T and B Cells in Transfusion-Related Immune Reactions: Cytokines and the Removal of Apoptic Material; L.A. Aarden. Involvement of B-cells in Peripheral Scrapic Pathogenesis; M. Klein. Alternative Approaches to Prevention of Alloimmunisation: A Virtue of Reality? J.Th.M. de Wolf. Transfusion-Associated Immunomodulation in Cancer Recurrence and Postoperative Infection: Meta-Analysis of Randomised Controlled Trials; E.C. Vamvakas. Does General Leukodepletion Provide Any Better Outcome?; C.L. van der Poel. Discussion. IV: Risk Management in Clinical Practice: Optimal vs Maximal. Haemovigilance: An Approach to Risk Management and Control; C.Th. Smit Sibinga. Evidence-Based Transfusion Medicine: A Fundamental Part of Risk Management; J. Kleijnen. Safety and Supply Issues from Consumers Point of View; B. O'Mahony. The Value of Education to Improve Perception, Acceptance and Communication of Transfusion-Related Risks; K.-F. Bopp. This is the Bloody Limit; T.A. Kok. The Virtue of Reality: Global Strategies in the Management of Transfusion-Related Risks; F. Delaney. Discussion. Index.
and post it to your social network
Most Helpful Customer Reviews
See all customer reviews >